Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

Fig. 1

Viability of a MV4-11, b MOLM-13, c OCI-AML-3, and d HL60 cells treated with idasanutlin and venetoclax alone and in combination for 72 h. CellTiter-Glo® assay (Promega) was used to determine the cellular viability. Data are displayed as mean plus standard deviation calculated from at least three biological replicates. In MV4-11 cells (a), combination treatment led to synergistic effects with a combination index (CI) of 0.72 and a relative IC50 of 8 nM compared to 55 and 18 nM for idasanutlin and venetoclax single treatment, respectively. In MOLM-13 cells (b), the calculated CI was 0.59 with an IC50 of 7 nM for the combination as opposed to single treatment with idasanutlin (IC50, 35 nM) and venetoclax (IC50, 20 nM). OCI-AML-3 cells were resistant to venetoclax (c), while p53 mutated HL-60 cells did not react up to 2 μM idasanutlin as expected (d)

Back to article page